Argus sees upside for United Therapeutics over the next year

Argus analyst Jasper Hellweg keeps a Buy rating and $280 price target on United Therapeutics, noting that while the stock has underperformed over the past three months with a decline of just under 1% versus an 8% gain for the S&P 500, the firm sees upside for share over the next year. Argus is citing United Therapeutics’ continued strong performance of Tyvaso, the study of Tyvaso for new indications, the promising organ manufacturing and transplant programs, and the company’s strong balance sheet and pipeline.